Characterization of the anti‐CD22 targeted therapy, moxetumomab pasudotox, for B‐cell precursor acute lymphoblastic leukemia
Moxetumomab pasudotox is a second‐generation recombinant immunotoxin against CD22 on B‐cell lineages. Antileukemic activity has been demonstrated in children with chemotherapy‐refractory B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL), with variable responses. Here, we report in vitro and in...
Gespeichert in:
| Veröffentlicht in: | Pediatric blood & cancer 2017-11, Vol.64 (11), p.n/a |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 11 |
| container_start_page | |
| container_title | Pediatric blood & cancer |
| container_volume | 64 |
| creator | Kinjyo, Ichiko Matlawska‐Wasowska, Ksenia Chen, Xiaoru Monks, Noel R. Burke, Patricia Winter, Stuart S. Wilson, Bridget S. |
| description | Moxetumomab pasudotox is a second‐generation recombinant immunotoxin against CD22 on B‐cell lineages. Antileukemic activity has been demonstrated in children with chemotherapy‐refractory B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL), with variable responses. Here, we report in vitro and in vivo evaluation of moxetumomab pasudotox treatment of human cell lines and patient‐derived cells as a preliminary study to understand characteristics of sensitivity to treatment. Binding, internalization, and apoptosis were evaluated using fluorescently tagged moxetumomab pasudotox. Studies in NOD‐scid IL2Rgnull mice showed a modest survival benefit in mice engrafted with 697 cells but not in NALM6 or the two patient‐derived xenograft models. |
| doi_str_mv | 10.1002/pbc.26604 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7501879</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1942671338</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4434-6db8dea278e2a19b05ca37b2d413bfa0350a8af3247005dd15e2ef1943f711e53</originalsourceid><addsrcrecordid>eNp1kctu1TAQhi1ERUthwQsgS6yQelpfc9kg0XApUiVYwNqaOJMelyQOttP2sOoj8Iw8CS6nHMGClS3P529G8xPyjLNjzpg4mVt7LIqCqQfkgGulV5rx8uHuzup98jjGy4wWTFePyL6olKolVwfktllDAJswuO-QnJ-o72laI4UpuZ-3P5o3QtAE4QITdneFAPPmiI7-BtMy-hFaOkNcOp_8zRHtfaCn-ZfFYaBzQLuEmJ_ALgnpsBnntW8HiMlZOuDyFUcHT8heD0PEp_fnIfny7u3n5mx1_vH9h-b1-coqJdWq6NqqQxBlhQJ43TJtQZat6BSXbQ9MagYV9FKokjHddVyjwJ7XSvYl56jlIXm19c5LO2JncUoBBjMHN0LYGA_O_FuZ3Npc-CtT5mVWZZ0FL-4FwX9bMCZz6Zcw5ZlNbiOKkktZZerllrLBxxiw33XgzNyFZXJY5ndYmX3-90g78k86GTjZAtduwM3_TebTabNV_gLb_KMe</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1942671338</pqid></control><display><type>article</type><title>Characterization of the anti‐CD22 targeted therapy, moxetumomab pasudotox, for B‐cell precursor acute lymphoblastic leukemia</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Kinjyo, Ichiko ; Matlawska‐Wasowska, Ksenia ; Chen, Xiaoru ; Monks, Noel R. ; Burke, Patricia ; Winter, Stuart S. ; Wilson, Bridget S.</creator><creatorcontrib>Kinjyo, Ichiko ; Matlawska‐Wasowska, Ksenia ; Chen, Xiaoru ; Monks, Noel R. ; Burke, Patricia ; Winter, Stuart S. ; Wilson, Bridget S.</creatorcontrib><description>Moxetumomab pasudotox is a second‐generation recombinant immunotoxin against CD22 on B‐cell lineages. Antileukemic activity has been demonstrated in children with chemotherapy‐refractory B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL), with variable responses. Here, we report in vitro and in vivo evaluation of moxetumomab pasudotox treatment of human cell lines and patient‐derived cells as a preliminary study to understand characteristics of sensitivity to treatment. Binding, internalization, and apoptosis were evaluated using fluorescently tagged moxetumomab pasudotox. Studies in NOD‐scid IL2Rgnull mice showed a modest survival benefit in mice engrafted with 697 cells but not in NALM6 or the two patient‐derived xenograft models.</description><identifier>ISSN: 1545-5009</identifier><identifier>EISSN: 1545-5017</identifier><identifier>DOI: 10.1002/pbc.26604</identifier><identifier>PMID: 28449314</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Acute lymphoblastic leukemia ; Adolescent ; Adult ; Animal models ; Animals ; Antineoplastic Agents - pharmacology ; Apoptosis ; Apoptosis - drug effects ; Bacterial Toxins - pharmacology ; CD22 antigen ; Cell Proliferation - drug effects ; Chemotherapy ; Child ; Child, Preschool ; Children ; Exotoxins - pharmacology ; Hematology ; Humans ; Immunotherapy ; Internalization ; Leukemia ; Lymphatic leukemia ; Lymphocytes B ; Male ; Mice ; Mice, Inbred NOD ; Mice, SCID ; Monoclonal antibodies ; Oncology ; Pediatrics ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - pathology ; Sialic Acid Binding Ig-like Lectin 2 - antagonists & inhibitors ; Targeted cancer therapy ; Tumor Cells, Cultured ; Xenograft Model Antitumor Assays ; Xenografts ; Young Adult</subject><ispartof>Pediatric blood & cancer, 2017-11, Vol.64 (11), p.n/a</ispartof><rights>2017 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4434-6db8dea278e2a19b05ca37b2d413bfa0350a8af3247005dd15e2ef1943f711e53</citedby><cites>FETCH-LOGICAL-c4434-6db8dea278e2a19b05ca37b2d413bfa0350a8af3247005dd15e2ef1943f711e53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpbc.26604$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpbc.26604$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28449314$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kinjyo, Ichiko</creatorcontrib><creatorcontrib>Matlawska‐Wasowska, Ksenia</creatorcontrib><creatorcontrib>Chen, Xiaoru</creatorcontrib><creatorcontrib>Monks, Noel R.</creatorcontrib><creatorcontrib>Burke, Patricia</creatorcontrib><creatorcontrib>Winter, Stuart S.</creatorcontrib><creatorcontrib>Wilson, Bridget S.</creatorcontrib><title>Characterization of the anti‐CD22 targeted therapy, moxetumomab pasudotox, for B‐cell precursor acute lymphoblastic leukemia</title><title>Pediatric blood & cancer</title><addtitle>Pediatr Blood Cancer</addtitle><description>Moxetumomab pasudotox is a second‐generation recombinant immunotoxin against CD22 on B‐cell lineages. Antileukemic activity has been demonstrated in children with chemotherapy‐refractory B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL), with variable responses. Here, we report in vitro and in vivo evaluation of moxetumomab pasudotox treatment of human cell lines and patient‐derived cells as a preliminary study to understand characteristics of sensitivity to treatment. Binding, internalization, and apoptosis were evaluated using fluorescently tagged moxetumomab pasudotox. Studies in NOD‐scid IL2Rgnull mice showed a modest survival benefit in mice engrafted with 697 cells but not in NALM6 or the two patient‐derived xenograft models.</description><subject>Acute lymphoblastic leukemia</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Animal models</subject><subject>Animals</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Apoptosis</subject><subject>Apoptosis - drug effects</subject><subject>Bacterial Toxins - pharmacology</subject><subject>CD22 antigen</subject><subject>Cell Proliferation - drug effects</subject><subject>Chemotherapy</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Children</subject><subject>Exotoxins - pharmacology</subject><subject>Hematology</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Internalization</subject><subject>Leukemia</subject><subject>Lymphatic leukemia</subject><subject>Lymphocytes B</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Inbred NOD</subject><subject>Mice, SCID</subject><subject>Monoclonal antibodies</subject><subject>Oncology</subject><subject>Pediatrics</subject><subject>Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</subject><subject>Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - pathology</subject><subject>Sialic Acid Binding Ig-like Lectin 2 - antagonists & inhibitors</subject><subject>Targeted cancer therapy</subject><subject>Tumor Cells, Cultured</subject><subject>Xenograft Model Antitumor Assays</subject><subject>Xenografts</subject><subject>Young Adult</subject><issn>1545-5009</issn><issn>1545-5017</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kctu1TAQhi1ERUthwQsgS6yQelpfc9kg0XApUiVYwNqaOJMelyQOttP2sOoj8Iw8CS6nHMGClS3P529G8xPyjLNjzpg4mVt7LIqCqQfkgGulV5rx8uHuzup98jjGy4wWTFePyL6olKolVwfktllDAJswuO-QnJ-o72laI4UpuZ-3P5o3QtAE4QITdneFAPPmiI7-BtMy-hFaOkNcOp_8zRHtfaCn-ZfFYaBzQLuEmJ_ALgnpsBnntW8HiMlZOuDyFUcHT8heD0PEp_fnIfny7u3n5mx1_vH9h-b1-coqJdWq6NqqQxBlhQJ43TJtQZat6BSXbQ9MagYV9FKokjHddVyjwJ7XSvYl56jlIXm19c5LO2JncUoBBjMHN0LYGA_O_FuZ3Npc-CtT5mVWZZ0FL-4FwX9bMCZz6Zcw5ZlNbiOKkktZZerllrLBxxiw33XgzNyFZXJY5ndYmX3-90g78k86GTjZAtduwM3_TebTabNV_gLb_KMe</recordid><startdate>201711</startdate><enddate>201711</enddate><creator>Kinjyo, Ichiko</creator><creator>Matlawska‐Wasowska, Ksenia</creator><creator>Chen, Xiaoru</creator><creator>Monks, Noel R.</creator><creator>Burke, Patricia</creator><creator>Winter, Stuart S.</creator><creator>Wilson, Bridget S.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7TO</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>5PM</scope></search><sort><creationdate>201711</creationdate><title>Characterization of the anti‐CD22 targeted therapy, moxetumomab pasudotox, for B‐cell precursor acute lymphoblastic leukemia</title><author>Kinjyo, Ichiko ; Matlawska‐Wasowska, Ksenia ; Chen, Xiaoru ; Monks, Noel R. ; Burke, Patricia ; Winter, Stuart S. ; Wilson, Bridget S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4434-6db8dea278e2a19b05ca37b2d413bfa0350a8af3247005dd15e2ef1943f711e53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Acute lymphoblastic leukemia</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Animal models</topic><topic>Animals</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Apoptosis</topic><topic>Apoptosis - drug effects</topic><topic>Bacterial Toxins - pharmacology</topic><topic>CD22 antigen</topic><topic>Cell Proliferation - drug effects</topic><topic>Chemotherapy</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Children</topic><topic>Exotoxins - pharmacology</topic><topic>Hematology</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Internalization</topic><topic>Leukemia</topic><topic>Lymphatic leukemia</topic><topic>Lymphocytes B</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Inbred NOD</topic><topic>Mice, SCID</topic><topic>Monoclonal antibodies</topic><topic>Oncology</topic><topic>Pediatrics</topic><topic>Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</topic><topic>Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - pathology</topic><topic>Sialic Acid Binding Ig-like Lectin 2 - antagonists & inhibitors</topic><topic>Targeted cancer therapy</topic><topic>Tumor Cells, Cultured</topic><topic>Xenograft Model Antitumor Assays</topic><topic>Xenografts</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kinjyo, Ichiko</creatorcontrib><creatorcontrib>Matlawska‐Wasowska, Ksenia</creatorcontrib><creatorcontrib>Chen, Xiaoru</creatorcontrib><creatorcontrib>Monks, Noel R.</creatorcontrib><creatorcontrib>Burke, Patricia</creatorcontrib><creatorcontrib>Winter, Stuart S.</creatorcontrib><creatorcontrib>Wilson, Bridget S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Pediatric blood & cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kinjyo, Ichiko</au><au>Matlawska‐Wasowska, Ksenia</au><au>Chen, Xiaoru</au><au>Monks, Noel R.</au><au>Burke, Patricia</au><au>Winter, Stuart S.</au><au>Wilson, Bridget S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Characterization of the anti‐CD22 targeted therapy, moxetumomab pasudotox, for B‐cell precursor acute lymphoblastic leukemia</atitle><jtitle>Pediatric blood & cancer</jtitle><addtitle>Pediatr Blood Cancer</addtitle><date>2017-11</date><risdate>2017</risdate><volume>64</volume><issue>11</issue><epage>n/a</epage><issn>1545-5009</issn><eissn>1545-5017</eissn><abstract>Moxetumomab pasudotox is a second‐generation recombinant immunotoxin against CD22 on B‐cell lineages. Antileukemic activity has been demonstrated in children with chemotherapy‐refractory B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL), with variable responses. Here, we report in vitro and in vivo evaluation of moxetumomab pasudotox treatment of human cell lines and patient‐derived cells as a preliminary study to understand characteristics of sensitivity to treatment. Binding, internalization, and apoptosis were evaluated using fluorescently tagged moxetumomab pasudotox. Studies in NOD‐scid IL2Rgnull mice showed a modest survival benefit in mice engrafted with 697 cells but not in NALM6 or the two patient‐derived xenograft models.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>28449314</pmid><doi>10.1002/pbc.26604</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1545-5009 |
| ispartof | Pediatric blood & cancer, 2017-11, Vol.64 (11), p.n/a |
| issn | 1545-5009 1545-5017 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7501879 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Acute lymphoblastic leukemia Adolescent Adult Animal models Animals Antineoplastic Agents - pharmacology Apoptosis Apoptosis - drug effects Bacterial Toxins - pharmacology CD22 antigen Cell Proliferation - drug effects Chemotherapy Child Child, Preschool Children Exotoxins - pharmacology Hematology Humans Immunotherapy Internalization Leukemia Lymphatic leukemia Lymphocytes B Male Mice Mice, Inbred NOD Mice, SCID Monoclonal antibodies Oncology Pediatrics Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - pathology Sialic Acid Binding Ig-like Lectin 2 - antagonists & inhibitors Targeted cancer therapy Tumor Cells, Cultured Xenograft Model Antitumor Assays Xenografts Young Adult |
| title | Characterization of the anti‐CD22 targeted therapy, moxetumomab pasudotox, for B‐cell precursor acute lymphoblastic leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T04%3A09%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Characterization%20of%20the%20anti%E2%80%90CD22%20targeted%20therapy,%20moxetumomab%20pasudotox,%20for%20B%E2%80%90cell%20precursor%20acute%20lymphoblastic%20leukemia&rft.jtitle=Pediatric%20blood%20&%20cancer&rft.au=Kinjyo,%20Ichiko&rft.date=2017-11&rft.volume=64&rft.issue=11&rft.epage=n/a&rft.issn=1545-5009&rft.eissn=1545-5017&rft_id=info:doi/10.1002/pbc.26604&rft_dat=%3Cproquest_pubme%3E1942671338%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1942671338&rft_id=info:pmid/28449314&rfr_iscdi=true |